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TRIM5a is a restriction factor that limits infection of human cells by so-called N- but not B- or NB-tropic strains of murine
leukemia virus (MLV). Here, we performed a mutation-based functional analysis of TRIM5a-mediated MLV restriction.
Our results reveal that changes at tyrosine
336 of human TRIM5a, within the variable region 1 of its C-terminal PRYSPRY
domain, can expand its activity to B-MLV and to the NB-tropic Moloney MLV. Conversely, we demonstrate that the
escape of MLV from restriction by wild-type or mutant forms of huTRIM5a can be achieved through interdependent
changes at positions 82, 109, 110, and 117 of the viral capsid. Together, our results support a model in which TRIM5a-
mediated retroviral restriction results from the direct binding of the antiviral PRYSPRY domain to the viral capsid, and
can be prevented by interferences exerted by critical residues on either one of these two partners.
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Introduction
Retroelements constitute important evolutionary forces
for the genome of higher organisms, yet their uncontrolled
spread, whether from endogenous loci or within the context
of retroviral infections, can cause diseases such as cancer,
autoimmunity and immunodeﬁciency, including AIDS. Cor-
respondingly, a variety of host-encoded activities limit this
process, behaving as the arms of a line of defence commonly
called intrinsic immunity, which notably contributes to
restricting the cross-species transmission of retroviruses [1].
The product of the Friend virus susceptibility 1 (Fv1) gene,
which shares similarity with the gag region of an endogenous
retrovirus, conditions the susceptibility of various mouse
strains to murine leukemia virus (MLV) [2,3]. N-tropic and B-
tropic MLV strains replicate in Swiss/NIH and in Balb/c mice,
respectively, reﬂecting the presence of either the n or the b
allele of Fv1 in the genome of these animals. A critical
determinant of the differential sensitivity of MLV strains to
Fv1 lies in amino acid 110 of the viral capsid (CA), which is an
arginine in the prototypic N-tropic MLV and a glutamate in
its B-tropic counterpart [4,5]. Moloney MLV (Mo-MLV)
harbors an alanine at this position and escapes both Fv1
n
and Fv1
b, hence is termed NB-tropic.
N-MLV is restricted too in some non-murine mammalian
cells, including of human origin, which do not encode Fv1.
Blockade is in these cases mediated by TRIM5a, a member of
the tripartite motif (TRIM) family of proteins [6–10]. TRIM5a
also prevents the cross-species transmission of primate
lentiviruses. The orthologues present in Old World monkeys,
including macaque rhesus, restrict human immunodeﬁciency
virus type 1 (HIV-1) and N-MLV, while those from New World
monkeys, tend to restrict simian immunodeﬁciency virus of
macaques (SIVmac) and for some species N-MLV but not HIV-
1 [11–13]. Human TRIM5a (huTRIM5a) blocks N-MLV, but is
only weakly active against SIVmac and HIV-1 [6–9,11,14].
All TRIM proteins contain a RING, a B-Box and a coiled-
coil region, which together constitute the so-called RBCC
domain [10,15,16]. TRIM5a further harbors at its C-terminus
the PRYSPRY or B30.2 domain, responsible for the viral
capsid-speciﬁc capture of restricted viruses [17–19]. Sequence
alignments of the PRYSPRY domains of various primate
TRIM5a and other related TRIM proteins reveal 4 variable
regions (V1, V2, V3 and V4), predicted to constitute surface-
exposed loops based on the structure of the homologous
domain of related proteins [12,20–23]. While V1, V2 and V3
were all found to contribute to the antiviral speciﬁcity of
TRIM5a orthologues [11], V1 was shown to play a most
critical role in this process. Within this loop, removing a
positive charge at position 332 or substituting residues 335 to
340 by an eight amino acid rhesus sequence confers
huTRIM5a with the ability to restrict HIV-1 [11,24,25].
Conversely, introducing residues 335–340 of huTRIM5a at
the corresponding locus of rhesus monkey TRIM5a
(rhTRIM5a) enhances the N-MLV blocking activity of the
simian protein [26].
The present study was designed to deﬁne further how
TRIM5a recognizes retroviral capsids. Our results indicate
that, if huTRIM5a efﬁciently restricts only N-MLV and not B-
MLV or Mo-MLV, this is due to the negative inﬂuence of a key
residue in V1. Conversely, MLV is capable of avoiding
restriction via the interdependent inﬂuences of a cluster of
amino acids exposed at the surface of its capsid.
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A Single Amino Acid Substitution in huTRIM5a PRYSPRY
Domain Extends Its Activity to B- and Mo-MLV
In order to characterize the interaction between
huTRIM5a and its viral targets, we introduced amino acid
changes in the central V1 region of its PRYSPRY domain. Cell
lines stably expressing the resulting mutants were generated
by retroviral vector-mediated transduction of permissive Fv1-
null Mus dunni tail ﬁbroblasts (MDTFs) (Figure 1). A ﬁrst series
of MDTF derivatives expressing huTRIM5a mutants carrying
single alanine substitutions at positions 334 to 339 were
challenged with MLV- or HIV-derived green ﬂuorescent
protein (GFP)-expressing vectors, scoring infection by ﬂuo-
rescence-activated cell sorting (FACS) analysis (Figures 1A
and 2A). All mutants conserved the ability to restrict N-MLV,
albeit at a slightly reduced efﬁciency for some (e.g., F
339A).
None could block HIV-1, except for F
339A that was lowly
active. In contrast, replacement of tyrosine
336 by alanine
yielded a mutant capable of efﬁciently blocking B-MLV and,
to a small extent, Mo-MLV.
We examined the step of the B-MLV replicative cycle
targeted by this expanded-spectrum huTRIM5a mutant.
Several reports have demonstrated that N-MLV blockade by
huTRIM5a occurs at an early post-entry stage, before reverse
transcription [7,13,27]. In contrast, the only restriction
activity so far identiﬁed against B-MLV is mediated by Fv1
n,
which allows viral DNA synthesis to proceed but inhibits viral
nuclear import [28,29]. We thus infected MDTF cell lines
expressing either wild-type or Y
336A huTRIM5a, or control
cells, with equal doses of N-, B- or Mo-MLV vectors and
monitored the accumulation of reverse transcription prod-
ucts by PCR, using primers that ampliﬁed elongated minus-
strand DNA (Figure 2B). All three vectors yielded readily
detectable reverse transcripts in control cells at 6 hours post-
infection. Consistent with previous studies, N-MLV DNA
levels were signiﬁcantly reduced in the presence of wild-type
huTRIM5a, whereas B-MLV escaped this effect. In contrast,
both N- and B-MLV exhibited strikingly reduced amounts of
reverse transcripts in cells expressing huTRIM5aY336A. With
Mo-MLV, a slight decrease in viral DNA was noted in cells
expressing this mutant at 8 hours post-infection, compared
with control or wild-type huTRIM5a-expressing cells. This
inhibition was more obvious when the analysis was repeated
at 5 days post-infection, that is, upon scoring the ultimate
proviral load of the cells, which correlated with the results of
the FACS analyses performed at the same time (Figure 2B and
2C). Altogether, these data indicate that wild-type and
huTRIM5aY336A similarly act before the completion of
reverse transcription.
Y
336 Exerts Negative Influence to Limit the Spectrum of
huTRIM5a Antiviral Activity
To explore further the modalities by which the Y
336A
mutation renders huTRIM5a active against B-MLV, we
generated MDTF cell lines expressing huTRIM5a derivatives
with other amino acid substitutions or with a deletion at this
position (Figure 1B). N-MLV restriction was unaffected by
any of these changes. In contrast, variable degrees of B-MLV
restriction were observed (Figure 3). Introduction of other
small amino acids besides alanine (threonine, serine, cysteine
Figure 1. Stable Expression of Wild-Type or PRYSPRY V1 Mutant Forms of
huTRIM5a
(A) Schematic representation of the domains present in huTRIM5a.
Numbers refer to the amino acid position. V1 through V4 designate the
four variable regions found in the PRYSPRY domain. The V1 amino acid
sequence is shown below, with mutated amino acids (334 to 339)
indicated with an asterisk (*). Below is a western blot analysis of extracts
from MDTF cells stably transduced with retroviral vectors expressing HA-
tagged versions of these huTRIM5a derivatives, using HA (top) and PCNA
(bottom)-specific antibodies.
(B) Same analysis, with derivatives carrying the indicated amino acid
substitutions or a deletion (D) at position 336.
doi:10.1371/journal.ppat.0030200.g001
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Author Summary
Mammalian cells are endowed with intrinsic lines of defence against
retroviruses, which notably contribute to limiting the cross-species
transmission of these pathogens. TRIM5a is one such restriction
factor, which acts by recognizing the capsid of incoming retro-
viruses through its C-terminal PRYSPRY domain. Human TRIM5a
potently blocks the so-called N-tropic murine leukemia virus (MLV),
but is ineffective against the closely related B-tropic and Moloney
strains. In this study, we demonstrate that substitution of a single
amino acid in the PRYSPRY domain of this protein expands its
antiviral activity to these other MLV strains. Conversely, we show
that protection of MLV from this restriction is governed by the
negative influence of specific residues at a few critical positions of
the retroviral capsid. These results support the model of a direct
interaction between TRIM5a and retroviral capsids, shedding light
on an important arm of innate antiretroviral immunity.Figure 2. HuTRIM5aY336A Potently Blocks B-MLV at an Early Stage of Infection
(A) MDTF cells expressing wild-type (WT) or indicated mutant forms of huTRIM5a, or transduced with a control vector (vector), were challenged with
serial 2-fold dilutions of MLV-based or HIV-1-based GFP vectors initially titered on permissive MDTF cells. Infections were scored at 48 hours post-
infection by FACS. Curves are representatives of at least two independent experiments, and phenotype observed with huTRIM5aY336A was confirmed
in three independently obtained stable cell lines.
(B) Cells expressing wild-type or Y
336A mutated huTRIM5a, or control cells (vector), were challenged with equal doses of N-, B- or Mo-MLV. Cellular DNA
extractions were performed before (0 h) or 6 h, 8 h or 5 days post-infection. Intermediate minus strand DNA reverse transcription products were
amplified by PCR. For each cell line, transduction was performed in triplicate in the absence (1, 2) or presence (-) of azidothymidine (AZT), a reverse
transcription inhibitor. Water (C
 ) and the plasmid pCNCG (C
þ) were used as negative and positive controls for the PCR. The mouse peripheral myelin
protein (Pmp22) gene was used as a loading control.
(C) In parallel of the experiment described in (B), the percentage of GFP-positive cells was determined 5 days post-infection by flow cytometry.
doi:10.1371/journal.ppat.0030200.g002
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Residues Influencing MLV Capsid-TRIM5a Recognitionand, to a lesser extent, proline), or removal of tyrosine
336, also
conferred a gain-of-function phenotype to huTRIM5a. One
mutant, huTRIM5aY336K, even acquired the ability to block
Mo-MLV with a good efﬁciency (Figure 3). This did not simply
reﬂect the presence of a positive charge at this position,
because the Y
336R mutation rendered huTRIM5a only weakly
active against B-MLV and even less so against Mo-MLV, even
though it might be due to its poor expression level. Notably,
replacing tyrosine
336 with glutamate or phenylalanine did not
broaden huTRIM5a restriction beyond N-MLV. Moreover,
none of the mutants acquired the ability to block HIV-1.
B-MLV Restriction Seems Incompatible with HIV-1
Blockade
It was previously demonstrated that a single amino acid
substitution or deletion at position 332 of huTRIM5a
provides this molecule with the ability to block HIV-1
infection [24,25,30]. We thus asked whether a molecule
carrying changes at both positions 332 and 336 restricts not
only N- and B-MLV, but also HIV-1. For this, we generated
MDTF cell lines expressing a series of huTRIM5a double
mutants, using various combinations of substitutions and
deletions previously noted as broadening the spectrum of
activity of the protein towards either B-MLV (this work) or
HIV-1 [24,25,30] (Figure 4A). Double mutants that included
an alanine substitution at position 336 were either poorly
expressed (R
332H/Y
336A, data not shown) or expressed but
without antiviral activity even against N-MLV (R
332A/Y
336A,
Figure 4B and 4C). All other double mutants were stably
expressed, and exhibited the MLV restriction patterns
expected from the residue present at position 336 (Figure
4B and 4C). Single mutants with arginine to proline, histidine,
alanine or a deletion at position 332 signiﬁcantly restricted
HIV-1, albeit it less efﬁciently than rhTRIM5a. However,
none of the double mutants was effective against this virus.
Furthermore, substitutions at position 332 somewhat reduced
the ability of huTRIM5aY336K to restrict Mo-MLV (Figure
4C). It thus appears that changes underlying the acquisition
of B- and Mo-MLV restriction ability preclude further
extension of the activity of huTRIM5a to HIV-1.
Context-Limited Influence of Residue 110 of the MLV
Capsid on Susceptibility to huTRIM5a-Mediated
Restriction
The effective blockade of both N- and B-MLV by several
huTRIM5a mutants strongly suggested that the ‘‘canonical’’
amino acid 110 of the MLV capsid, the importance of which
for Fv1
n and Fv1
b sensitivity has been extensively demon-
strated [4,5,27], did not play an essential role in the case of
TRIM5a. The N- and B-MLV packaging constructs sequence
used in the present study encode for viral capsids that differ
in only three residues (CA109, CA110 and CA159) [27,31,32].
Exchanging the residue present in either virus at position 110,
through reciprocal arginine-glutamate exchanges, sufﬁced to
confer wild-type huTRIM5a susceptibility or resistance to N-
and B-MLV. However, both mutants were potently blocked by
huTRIM5aY336A, which also restricted either N- or B-MLV
modiﬁed to contain an alanine at this position (Figure 5A).
These data conﬁrmed that TRIM5a can be altered to act in a
CA110-independent manner. However, in the context of Mo-
MLV, this capsid residue plays a pivotal role. Mo-MLV could
indeed escape all forms of TRIM5a-mediated blockade when
alanine
110 of its capsid was changed to glutamate. Inversely,
when arginine was introduced instead, Mo-MLV restriction
by huTRIM5aY336K and huTRIM5aY336A was strengthened,
and the virus became slightly sensitive to wild-type TRIM5a,
as recently noted [33] (Figure 5B).
CA82, CA109, CA110, and CA117 Interdependently Affect
MLV Sensitivity to huTRIM5a
We then sought to deﬁne which other capsid residues
inﬂuence MLV susceptibility to huTRIM5a-mediated block-
Figure 3. Differential Restriction Spectrum of huTRIM5a Y
336 Mutants
MDTF cells expressing indicated huTRIM5a derivatives, as documented in Figure 1B, were challenged with serial dilutions of MLV- and HIV-based GFP
vectors, and analyzed by flow cytometry 2 days later. The resulting infectivity curves are representatives of at least two independent experiments.
doi:10.1371/journal.ppat.0030200.g003
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Residues Influencing MLV Capsid-TRIM5a Recognitionade. For this, we focused on amino acids in N- or B-MLV that
differ from Mo-MLV, and on positions previously demon-
strated to inﬂuence restriction by huTRIM5a and/or Fv1
(Figure 6A) [34,35]. We found that single point mutations at
positions 82 (N to D) or 117 (L to H) of capsid allowed B-MLV
to escape completely huTRIM5aY336A restriction (Figure 6B).
Nevertheless, the inﬂuence of these two mutations was
context-dependent, because when introduced in N-MLV they
relieved neither wild-type nor huTRIMaY336A-mediated
restriction (Figure 6B). Furthermore, the newly introduced
residues are those naturally present in Mo-MLV, which is
blocked by huTRIM5aY336K (Figures 3 and 5B). The testing of
a high number of additional single and combined mutants
conﬁrmed that MLV susceptibility to TRIM5a-mediated
restriction is dictated by the interdependent inﬂuences of
capsid residues 82, 109, 110 and 117 with a minor modulation
by residue 159 (Figure 7).
Discussion
It is suspected, albeit not yet formally demonstrated, that
TRIM5a-mediated retroviral restriction proceeds through the
direct binding of the antiviral PRYSPRY domain to the capsid
of incoming viruses [13,17,18,24,27]. The present study, which
demonstrates that the consequences of mutations in the
huTRIM5a PRYSPRY V1 can be counterbalanced by changes
in the MLV capsid, and vice versa, lends strong credence to
such a model.
This work stands out by its identiﬁcation of a residue,
tyrosine
336 of huTRIM5a, which limits the spectrum of MLV
targets of this antiviral to the sole N-tropic MLV. A number of
amino acid substitutions at this position, as well as a deletion
of this residue, confer huTRIM5a with the additional ability
to block B-MLV, and introduction of a lysine even expands
restriction to Mo-MLV. Understanding fully the mechanism
of this gain of function would require a determination of the
tri-dimensional structure of the TRIM5a-capsid complex. In
its absence, the crystal structures of the PRYSPRY domain of
related proteins, PRYSPRY-19q13.4.1, GUSTAVUS and
TRIM21, suggests that the V1 region of huTRIM5a could
form a protruding loop with tyrosine
336 situated underneath
and in direct contact (at a less than 4 A ˚ distance) with residues
in the V2 loop, which could limit the conformational
ﬂexibility of V1 [20–22]. However, the PRYSPRY V1 loops
of TRIM5a and these other proteins differ in length,
precluding ﬁrm analogy [23]. Alternatively, tyrosine
336 may
prevent the docking of V1 into its putative capsid-binding site
by steric hindrance. This would be consistent with the ﬁnding
that changes that most effectively broaden the spectrum of
Figure 4. B-MLV and HIV Restriction Are Mutually Exclusive
(A) Single and double point mutations (*) were introduced at positions 332 and 336 in the V1 region of huTRIM5a as illustrated.
(B) MDTF cell lines stably expressing these mutants were engineered by retroviral transduction, and analyzed by western blot as described in Figure 1.
(C) These cells were challenged with 2-fold dilutions of either N-MLV, B-MLV, Mo-MLV or HIV-derived GFP-expressing vectors, and infections were scored
by flow cytometry as described in Figure 2. Plots are representative of at least two independent experiments.
doi:10.1371/journal.ppat.0030200.g004
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Residues Influencing MLV Capsid-TRIM5a Recognitionaction of huTRIM5a are the removal of this tyrosine or its
substitution by small amino acids. However, the observation
that Y
336K further expands the restriction spectrum of
huTRIM5a not only to B- but also to Mo-MLV suggests that
this model may be overly simplistic. Arginine
332 of huTRIM5a
was similarly found to interfere with ability of huTRIM5a to
restrict HIV-1 and SIVmac [30]. In this case too, distinct amino
acid changes differentially affected the strength with which
either one of these two viruses was inhibited, suggesting that
both positive and negative inﬂuences are at play. As well, our
failure to generate a TRIM5a variant capable of blocking both
N- and B-MLV on the one hand and HIV-1 on the other hand,
by combining mutations at positions 332 and 336, points to
more complex inﬂuences within V1 itself. cis-acting interfer-
ences have also been noted in Fv1, where the C-terminal part
of Fv1
b was shown to prevent this factor from blocking B-
MLV, and where substitution of lysine
358 of Fv1
n by alanine
could extend the restriction spectrum of this antiviral to N-
MLV [36].
On the viral capsid side, our study indicates that at least
four positions (CA82, CA109, CA110 and CA117) interde-
pendently condition MLV susceptibility to huTRIM5a,
whether in its wild-type or mutant forms. The inﬂuence of
each of these four residues varies according to both the virus
involved and the sequence of the TRIM5a PRYSPRY V1
region. Here, all viruses tested escaped wild-type huTRIM5a if
they harbored a glutamic acid at position 110 of capsid. As
such, E
110 dominantly interfere with restriction. However, a
Figure 5. Context-Specific Influence of MLV Capsid Residue 110
MDTF cells stably expressing wild-type or mutant versions of huTRIM5a, or containing a control vector, were challenged with N-, B- or Mo-MLV-derived
vectors packaged with wild-type or CA110-mutated capsids, as indicated. Infections were scored as described in Figure 2.
doi:10.1371/journal.ppat.0030200.g005
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Residues Influencing MLV Capsid-TRIM5a Recognitionrecent study demonstrated that wild-type huTRIM5a could
efﬁciently block an MLV retroviral vector packaged with a
capsid derived from a primate endogenous retrovirus
(PtERV) carrying a glutamic acid at this position [37]. As
well, we found here that the protective effect of E
110 could be
abrogated by substitutions of Y
336 in huTRIM5a, in which
case CA82 and CA117 became determinant. Indeed, with N-
and B-MLV-derived viruses, an aspartate at CA82 additionally
Figure 6. MLV CA82 and CA117 Can Interfere with TRIM5a-Mediated Restriction
(A) Amino acids sequence alignments of Mo-, N- and B-MLV capsids. Residues that differ between Mo-MLV and N-MLV and/or B-MLV are highlighted in
grey. The residues in italics at positions 109, 110 and 159 represent the only amino acids differences between N- and B-MLV capsids. Positions targeted
by site-directed mutagenesis in the present study are indicated by an arrow.
(B) Infectivity assays with indicated cell lines and vectors, performed as described in Figure 2. Residues at positions 82 and 117 exert different influences
whether in an N- or B-MLV context.
doi:10.1371/journal.ppat.0030200.g006
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Residues Influencing MLV Capsid-TRIM5a Recognitionallowed escape from TRIM5aY336A, and a histidine at CA117
from TRIM5aY336A and TRIM5aY336K. When CA110 was
occupied by an arginine, the picture was completely reversed,
as this residue dominantly potentiates susceptibility. Finally,
with an alanine at CA110, H
117 and D
82 induced escape from
wild-type TRIM5a, albeit in a CA109-dependent fashion, yet
viruses remained sensitive to Y
336-mutated forms of the
restriction factor.
A picture is thus emerging from these data, whereby CA110
plays the role of primary determinant of restriction, with
CA82, CA109 and CA117 acting as secondary modulators in a
V1-conditioned fashion. However, the restriction pattern
obtained with derivatives of Mo-MLV, which differs from the
N- and B-MLV strains used here at nine CA positions besides
these four, does not fully ﬁt with this model, indicating its
modulation by at least some of these other CA residues.
Notably, a recent study demonstrated the importance of
CA214 in potentiating Fv1
n-mediated restriction of Mo-MLV
only when CA110 was occupied by a glutamate [33].
MLV CA82, CA109, CA110 and CA117 were also demon-
strated to exert combinatorial inﬂuences on Fv1-mediated
restriction [35]. In spite of this parallel, sequences leading to
resistance or susceptibility to Fv1 and huTRIM5a are not
identical. For instance, whereas Fv1
b and huTRIM5a both
potently restrict CAE110A B-MLV, an additional N
82D
mutation allows escape from huTRIM5a (this work) but not
from Fv1
b [35]. Also, huTRIM5aY336A-mediated blockade of
B-MLV is relieved by change at CA117, which was previously
shown not to affect restriction by Fv1
n [35].
The structure of the amino-terminal part of the N-MLV
capsid in its hexameric state was resolved at a 2.5 A ˚ resolution
[38] (Figure 8). A monomer consists of two-stranded b-
hairpins followed by six a helices. Interestingly, CA82, CA109,
CA110 and CA117 are situated at the edge of a cavity formed
by helices 4 to 6 (Figure 8). CA82 sits between helix 4 and 5 at
the top of this pocket, across from CA109 and 110 on helix 6.
CA117 is further down along the helix 6 side of the cavity. At
least two scenarios can thus be envisioned for the binding of
huTRIM5a to the MLV capsid. First, it might rely on the sum
of individual interactions between TRIM5a residues, for
instance in the PRYSPRY V1 loop, and capsid amino acids
including 82, 109, 110 and 117. The non-essential nature of
any of these four capsid positions for susceptibility or
resistance to TRIM5a argues against this model, even though
it is conceivable that the abrogation of some of these
interactions might be compensated by the strengthening of
others. In a second scenario, the TRIM5a-binding site would
be located deeper in the pocket. This part of the protein is
constituted by residues that are highly conserved, hence most
probably play essential structural functions prohibiting
mutation [38]. Escape could then be achieved by mounting
obstacles to TRIM5a penetration into this pocket through
changes at the more ﬂexible yet critically placed CA82,
CA109, CA110 and CA117 residues. By analogy, it is
Figure 7. Susceptibility to huTRIM5a-Mediated Restriction of Various MLV Derivatives
aIn addition to CA110, CA82, CA109, CA117, and CA159, Moloney MLV capsid differs from N- and B-MLV CA at eight other positions (CA4, CA46, CA147,
CA202, CA214, CA229, CA242, CA244).
Fold restriction: -, less than 2; (þ), 2 to 5; þ, 5 to 10; þþ, more than 10 (calculated as described in Materials and Methods); ND: not done.
The one-letter abbreviation of amino acids was used to designate residues present at CA110, CA82, CA109, CA117, and CA159 (A: alanine, D: aspartate,
E: glutamate, G: glycine, H: histidine, L: leucine, N: asparagine, Q: glutamine, R: arginine, T: threonine).
doi:10.1371/journal.ppat.0030200.g007
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Residues Influencing MLV Capsid-TRIM5a Recognitioninteresting to note that the cyclophilin-binding loop of the
HIV-1 capsid, which has been postulated to interfere with the
blockade of this virus by wild-type huTRIM5a, hangs over a
very similar pocket formed by helices 4 to 7 of the structurally
homologous lentiviral capsid [38,39]. As such, this loop,
whether bound to or modiﬁed by cyclophilin A (CypA), could
function as a lid to prevent huTRIM5a from accessing its
HIV-1 CA binding site. However, recent data, which indicate
that the positive effects of CypA binding to CA on HIV-1
replication do not depend upon the presence of huTRIM5a
suggest that a strict parallel cannot be established between
restriction of MLV and HIV by the cellular antiviral [40–42].
Materials and Methods
Cell lines and culture. Mus dunni tail ﬁbroblasts (MDTFs) and
human embryonic kidney 293T cells (HEK 293T) were purchased
from the American Type Culture Collection (ATCC). All cell lines
were cultivated in Dulbecco’s modiﬁed Eagle medium supplemented
with 10% fetal calf serum, 2 mM glutamine and antibiotics (100 U/ml
penicillin, 100 mg/ml streptomycin).
Plasmids. MLV-based particles were produced using packaging
constructs containing Moloney MLV (pCIGPB), N- and B-tropic MLV
CA (pCIG3-N and pCIG3-B) kindly provided by O. Danos and J. Stoye,
respectively [32]. The GFP-encoding vector construct for all MLV
reporter viruses was pCNCG kindly provided by R. Zufferey.
Lentiviruses-based vectors were produced with the packaging
construct psPAX2 (Figures 2A and 3) or pR8.74 (Figure 4) and the
vector pWPTS-GFP (Figures 2A and 3) or pRRLsin PGK GFP (Figure
4). The env construct for all viral productions was pMD2G plasmid
expressing vesicular stomatitis virus G protein. Many plasmids used
are distributed by Addgene (http://www.addgene.org/).
The MLV plasmid encoding human TRIM5a was a kind gift of J.
Sodroski and was already described [13]. The amino acid coding
sequence of human TRIM5a with a C-terminal epitope derived from
inﬂuenza virus hemagglutinin (HA) was inserted in pLPCX MLV
vector construct (Clontech) allowing for puromycin selection of
transduced cells. Site-directed mutagenesis on pLPCX-huTRIM5a-
HA, pCIG3-N, pCIG3-B and pCIGPB was performed with the XL
QuickChange mutagenesis kit from Stratagene. Primers used are
listed in Table S1. Proper site-directed mutagenesis was checked by
sequencing reactions.
Viral production. All vector productions were performed by
CaPO4-mediated transient co-transfection of the retroviral vector,
gag-pol and env encoding constructs (http://tronolab.epﬂ.ch/; with
some minor adjustments). Brieﬂy, subconﬂuent HEK 293T cells were
co-transfected with 21.5 lg of vectors, 14.6 lg packaging constructs
and 7.9 lg env constructs in a 15-cm plate. Cells were washed 16 hours
post-transfection and supernatants were harvested 12, 24 and 36
hours later. Recombinant retroviral vectors containing supernatants
were centrifugated, ﬁltrated, and in some cases were concentrated by
ultracentrifugation. Titrations were performed on Fv1-null MDTF
cells.
Engineering of stable wild-type and mutant TRIM5a-expressing
cell line. MLV-based retroviral vectors encoding wild-type or point
mutants of human TRIM5a were produced using the pLPCX-derived
plasmids as described above. Viral supernatants containing recombi-
nant retroviral vectors were added on 5310
4 MDTF cells. Forty-eight
hours post-transduction, cells were expanded and selection for stably
transduced cells was performed by adding puromycin (Sigma) at a
concentration of 5 lg/ml. Cells were maintained continuously in the
presence of puromycin.
To evaluate TRIM5a expression level, total proteins were extracted
in a radioimmune precipitation assay buffer (phosphate-buffered-
saline (PBS) with 1% NP-40, 0.5% sodium deoxycholate and 0.1%
SDS) supplemented with protease inhibitor cocktail (Calbiochem).
Equal amounts of protein were resolved on a Tris-glycine SDS-
Polyacrylamide gel followed by western blot. HA-tagged proteins were
Figure 8. Highlighting of Functionally Critical Positions on the Structure of the MLV Capsid
Visualization of the previously defined structure of the N-terminal domain of the N-MLV capsid in its hexameric state, each monomer being given a
different color. Secondary structures in one monomer with the six a helices (a1–6) and two b-hairpins (b1 and b2) are represented in the lower right
panel. The four residues at positions 82, 109, 110 and 117 are shown with their respective side chains. Atoms in the side chains are colored in grey for
carbon, white for hydrogen, red for oxygen and blue for nitrogen. In the upper right panel, the molecular surface of the area framed in the red-colored
monomer is enlarged and viewed in the orientation indicated by the arrow. Surfaces of the four residues at positions 82, 109, 110, and 117 are colored.
doi:10.1371/journal.ppat.0030200.g008
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Residues Influencing MLV Capsid-TRIM5a Recognitiondetected using peroxydase-conjugated rat monoclonal antibody (clone
3F10, Roche). Proliferating cell nuclear antigen (PCNA) was used as a
protein loading control and was detected using a mouse monoclonal
antibody (clone PC10, Calbiochem) followed by a secondary sheep
anti-mouse antibody conjugated to horseradish peroxidase.
Reverse transcript detection. MDTF cells stably expressing wild-
type huTRIM5a, huTRIM5aY336A or stably transduced with the
empty pLPCX construct as a control were seeded at 2.5310
4 in a 24-
well plate. N-, B- and Mo-MLV viral stocks encoding GFP were treated
with DNAse I (20 lg/ml) in the presence of MgCl2 (10 mM) for 30
minutes at 378C. Cells were then transduced at an equal low
multiplicity of infection. For all time points and for each cell line,
a PCR negative control with azidothymidine (62.5 lM, Calbiochem)
pre-treated cells was included. Cells were then harvested before
transduction and 6 or 8 hours post-transduction. DNA was then
extracted using the DNAeasy Tissue extraction kit from Quiagen. To
detect the presence of provirus, cells were also collected 5 days post-
transduction and processed for DNA extraction and FACS analysis.
PCR reactions were performed using 5 ll of DNA extract. PCR
ampliﬁed a region from the neomycin resistance gene (forward
primer: 5’ GCGTTGGCTACCCGTGATATTG 3’) to the cytomegalo-
virus promoter (reverse primer: 5’ TGGGCTATGAACTAATGACC 3’)
present in the intermediate reverse transcript resulting from RNA
expressed by pCNCG. Mus musculus peripheral myelin protein
(Pmp22, NM_008885) was used as a normalization gene (forward
primer: 5’ TTCGTCAGTCCCACAGTTTTCTC 3’, reverse primer: 5’
ACTCGCTAGTCCCAA GGGTCTA 3’).
Infection with GFP reporter vectors and calculation of the fold
restriction. MDTF stable cell lines were seeded at 2.5 3 10
4 and
transduced 24 hours later with 2-fold serial dilutions of GFP reporter
vectors. Cells were harvested 48 hours post-transductions and ﬁxed in
1% formaldehyde-containing PBS. The percentage of GFP-positive
cells was determined by ﬂow cytometry using the Beckton Dickinson
FACScan or the multi-well plate reader Beckman Coulter Cell lab
Quanta Flow Cytometer. Results were analysed with FlowJo 8.1.1
software.
To calculate the fold restriction of the different MLV capsid
mutants by huTRIM5a derivatives, a ratio was performed between the
percentage of GFP-positive cellsi nt h ea b s e n c e( c e l l ss t a b l y
transduced with the empty vector) and presence of huTRIM5a
derivatives (cells stably expressing wild-type or mutants huTRIM5a).
Ratios were calculated with each dose of GFP vector from at least two
independent infections, and the average of these ratios was used for
the semi-quantitative scoring given in Figure 7.
Molecular imaging. The resolved structure of the N-terminal
domain of N-MLV capsid in its hexameric state ([38]; PDB: 1U7K) was
visualized using the UCSF Chimera software as described [43].
Supporting Information
Table S1. Sequences of the Primers Used for the Site-Directed
Mutagenesis
Modiﬁed nucleotides to generate the speciﬁed amino acid substitu-
tion are highlighted in bold and are underlined. Site where
nucleotides were removed to create amino acid deletion are
indicated with ‘‘//’’.
Found at doi:10.1371/journal.ppat.0030200.st001 (29 KB XLS).
Accession Numbers
The National Center for Biotechnology Information (http://www.ncbi.
nlm.nih.gov/) accession numbers for the proteins discussed in this
paper are human TRIM5a (AY625000), peripheral myelin protein
Pmp22 (NM_008885), and Rhesus TRIM5a (AY523632).
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